Bayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk

Dow Jones03-04

0832 GMT - Bayer's fourth-quarter results came in better than expected, but its 2026 outlook points to cuts to consensus estimates due to foreign-exchange rates, analysts at J.P. Morgan say in a research note. The German agricultural and pharmaceutical group reported quarterly sales that beat consensus estimates by 1%, mainly thanks to its agricultural business, the analysts say. Adjusted earnings beat consensus forecasts by 3%, driven by both pharma and agriculture, they add. Bayer's outlook implies a cut of around 3% to consensus estimates on 2026 adjusted Ebitda, largely related to currencies, according to JPM. Nevertheless, investors seem more focused on the outcome of Bayer's proposed Roundup settlement and the U.S. Supreme Court decision than on results, the analysts say. Shares fall 3.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 04, 2026 03:32 ET (08:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616801425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 16:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616801425","market":"hk","top_or_hot":-1,"title":"Bayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0832 GMT - Bayer's fourth-quarter results came in better than expected, but its 2026 outlook points to cuts to consensus estimates due to foreign-exchange rates, analysts at J.P. Morgan say in a research note. The German agricultural and pharmaceutical group reported quarterly sales that beat consensus estimates by 1%, mainly thanks to its agricultural business, the analysts say. Adjusted earnings beat consensus forecasts by 3%, driven by both pharma and agriculture, they add. Bayer's outlook implies a cut of around 3% to consensus estimates on 2026 adjusted Ebitda, largely related to currencies, according to <a href=\"https://laohu8.com/S/JPM\">JPM</a>. Nevertheless, investors seem more focused on the outcome of Bayer's proposed Roundup settlement and the U.S. Supreme Court decision than on results, the analysts say. Shares fall 3.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2026 03:32 ET (08:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-04 16:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0832 GMT - Bayer's fourth-quarter results came in better than expected, but its 2026 outlook points to cuts to consensus estimates due to foreign-exchange rates, analysts at J.P. Morgan say in a research note. The German agricultural and pharmaceutical group reported quarterly sales that beat consensus estimates by 1%, mainly thanks to its agricultural business, the analysts say. Adjusted earnings beat consensus forecasts by 3%, driven by both pharma and agriculture, they add. Bayer's outlook implies a cut of around 3% to consensus estimates on 2026 adjusted Ebitda, largely related to currencies, according to <a href=\"https://laohu8.com/S/JPM\">JPM</a>. Nevertheless, investors seem more focused on the outcome of Bayer's proposed Roundup settlement and the U.S. Supreme Court decision than on results, the analysts say. Shares fall 3.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2026 03:32 ET (08:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616801425","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616801425","pubTimestamp":1772613120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0832 GMT - Bayer's fourth-quarter results came in better than expected, but its 2026 outlook points to cuts to consensus estimates due to foreign-exchange rates, analysts at J.P. Morgan say in a research note. The German agricultural and pharmaceutical group reported quarterly sales that beat consensus estimates by 1%, mainly thanks to its agricultural business, the analysts say. Adjusted earnings beat consensus forecasts by 3%, driven by both pharma and agriculture, they add. Bayer's outlook implies a cut of around 3% to consensus estimates on 2026 adjusted Ebitda, largely related to currencies, according to JPM. Nevertheless, investors seem more focused on the outcome of Bayer's proposed Roundup settlement and the U.S. Supreme Court decision than on results, the analysts say. Shares fall 3.4%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4007":"制药"},"translate_title":"拜耳超出预期，但货币逆风影响前景——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"0832 GMT - Bayer's fourth-quarter results came in better than expected, but its 2026 outlook points to cuts to consensus estimates due to foreign-exchange rates, analysts at J.P. Morgan say in a research note. The German agricultural and pharmaceutical group reported quarterly sales that beat consensus estimates by 1%, mainly thanks to its agricultural business, the analysts say. Adjusted earnings beat consensus forecasts by 3%, driven by both pharma and agriculture, they add. Bayer's outlook implies a cut of around 3% to consensus estimates on 2026 adjusted Ebitda, largely related to currencies, according to JPM. Nevertheless, investors seem more focused on the outcome of Bayer's proposed Roundup settlement and the U.S. Supreme Court decision than on results, the analysts say. Shares fall 3.4%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 03:32 ET (08:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616801425","isCrawlerRequest":true}